{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["134(2)"],"submitter":["Phillips R"],"pubmed_abstract":["<h4>Background</h4>The Experimental Cancer Medicine Centre (ECMC) Network supports UK-wide access to experimental cancer therapies, many of which require specific genomic alterations. This study aimed to develop expert consensus on essential genes for a pan-cancer sequencing panel, involving subject matter experts (SMEs) from the ECMC Network and the pharmaceutical industry.<h4>Methods</h4>A pilot with 8 SMEs graded 526 genes, refining the list to 210. A three-round Delphi process was then used, with SMEs iteratively evaluating each gene. In the final round, SMEs also assessed the inclusion of tumour mutational burden (TMB), microsatellite instability (MSI), and mutation types (structural variations, copy number variations, and/or fusions).<h4>Results</h4>Consensus was reached on a final p"],"journal":["British journal of cancer"],"pagination":["289-294"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12820137"],"repository":["biostudies-literature"],"pubmed_title":["Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology."],"pmcid":["PMC12820137"],"pubmed_authors":["O'Carrigan B","Hargrave D","Ronghe M","Walter HS","Crabb SJ","Roxburgh P","Shaw PHS","Vedi A","Meissner M","Basu B","Lopez J","Tweddle DA","Zabkiewicz J","Symeonides S","Parkes EE","Sarker D","Savage KI","Phillips R","Butt Z","Middleton GW","Beloueche M","Cook N","Beggs AD","Greystoke A","Kureeman MY","McKeeve C","Jones R"],"additional_accession":[]},"is_claimable":false,"name":"Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology.","description":"<h4>Background</h4>The Experimental Cancer Medicine Centre (ECMC) Network supports UK-wide access to experimental cancer therapies, many of which require specific genomic alterations. This study aimed to develop expert consensus on essential genes for a pan-cancer sequencing panel, involving subject matter experts (SMEs) from the ECMC Network and the pharmaceutical industry.<h4>Methods</h4>A pilot with 8 SMEs graded 526 genes, refining the list to 210. A three-round Delphi process was then used, with SMEs iteratively evaluating each gene. In the final round, SMEs also assessed the inclusion of tumour mutational burden (TMB), microsatellite instability (MSI), and mutation types (structural variations, copy number variations, and/or fusions).<h4>Results</h4>Consensus was reached on a final p","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-06T19:29:50.613Z","creation":"2026-06-04T03:11:03.308Z"},"accession":"S-EPMC12820137","cross_references":{"pubmed":["41206382"],"doi":["10.1038/s41416-025-03252-6"]}}